污染监测在临床运动康复中的有效性 (EPIC-AIR)
临床运动康复中污染监测的有效性(EPIC-AIR)
The primary objective of EPIC-AIR is to evaluate the feasibility and potential effectiveness of integrating real-time air pollution monitoring into cardiac rehabilitation (CR) and pulmonary rehabilitation (PR) programmes via an online platform that delivers both exercise prescription and air pollution guidance. Specific objectives are: (1) to determine whether access to real-time air quality data reduces modelled ambient pollution exposure (PM2.5, PM10 and NO2) during outdoor physical activity in CR/PR patients and healthy volunteers; (2) to assess the feasibility of the trial design, including recruitment, randomisation, retention, adherence and completeness of outcome data; (3) to measure the impact of the intervention on physical activity levels, health-related quality of life and cardiovascular biomarkers; and (4) to inform the design and sample size of a future definitive randomised controlled trial
研究概览
地位
详细说明
EPIC-AIR is a single-site, stratified, blinded, two-arm randomised controlled feasibility trial conducted at University Hospitals of Leicester NHS Trust. Up to 80 participants comprising cardiac rehabilitation patients, pulmonary rehabilitation patients and healthy volunteers will be recruited. Following a 1-week baseline monitoring period, participants will be stratified by participant group (cardiac rehabilitation, pulmonary rehabilitation or healthy volunteer) and randomised 1:1 within strata using a computer-generated allocation sequence via the Sealed Envelope secure web-based system.
All participants will receive a Fitbit Charge 6 and a 12-week progressive walking programme delivered through the P-STEP platform. Participants allocated to the intervention arm will additionally receive real-time local PM2.5, PM10 and NO2 information and adaptive guidance concerning the timing, location, route or intensity of outdoor activity. Participants in the control arm will use the same platform and receive the same exercise guidance but without air-quality information or pollution-related guidance.
The primary outcomes are three co-primary pollutant-specific measures: weekly time-weighted mean modelled ambient PM2.5, PM10 and NO2 concentrations during moderate-to-vigorous physical activity (MVPA). Time-stamped GPS locations recorded during activity will be linked to wearable-derived activity data and contemporaneous modelled air-quality concentrations. These outcomes represent modelled ambient concentrations encountered during recorded activity rather than directly measured personal inhaled dose.
Weekly pollution exposure during the 12-week intervention will be analysed using repeated-measures mixed-effects models accounting for participant clustering, baseline exposure, study week, randomisation stratum, sex and calendar week. The principal treatment contrast will be the adjusted average intervention-control difference across the 12-week post-allocation period. Multiplicity across the three co-primary pollutants will be controlled using the Holm procedure.
The registered secondary outcome is weekly physical activity derived from wrist-worn accelerometry. Additional clinical, physiological and patient-reported outcomes will be explored. Feasibility outcomes include recruitment, retention, adherence, completeness of outcome data and adverse events. A final follow-up assessment will take place 3 months after completion of the 12-week intervention. No participants had been recruited at the time the registry record was revised.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:James A Donaldson, Ph.D
- 电话号码:+447990571690
- 邮箱:jad72@leicester.ac.uk
学习地点
-
-
Leicestershire
-
Leicester、Leicestershire、英国、LE39QP
- Glenfield Hospital, University Hospitals of Leicester NHS Trust, Groby Road
-
接触:
- James Donaldson, Ph.D
- 电话号码:0300 303 1573
- 邮箱:jad72@leicester.ac.uk
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Cohort A: Patients with long-term conditions Inclusion criteria for Cohort A are: male or female adults aged ≥18 years; clinical diagnosis of one or more of asthma, COPD, interstitial lung disease (ILD), coronary heart disease (CHD), or heart failure (HF), and signed off for exercise rehabilitation by a clinician; ownership of a GPS-enabled smartphone with internet access; ability to walk outdoors for a minimum of 5 minutes without feeling uneasy or unsteady; availability to complete the 1-week baseline period, 12-week intervention and 3-month post-intervention follow-up within the planned study period; willingness and ability to give informed consent; and willingness to wear a Fitbit device for >70% of the study duration.
- Inclusion criteria for Cohort B are identical to Cohort A, with the exception that participants must have no diagnosis of asthma, COPD, ILD, CHD, or HF.
Exclusion Criteria:
- Exclusion criteria for both cohorts are: diagnosis of dementia, learning disability, severe mental health disorders (excluding depression or anxiety), or epilepsy; receiving palliative care; insufficient English language ability to understand study documentation and use the platform; having been advised not to exercise by a healthcare professional within the past 12 months; currently pregnant; presence of chest pain at rest; and marked unsteadiness when standing or walking.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Air Quality Information Provided
Participants receive the 12-week progressive walking programme through the P-STEP platform together with real-time PM2.5, PM10 and NO2 information and adaptive pollution-related guidance concerning exercise route, timing and/or intensity. |
Participants will receive a progressive, personalised walking exercise programme aimed to increase their weekly levels of physical activity over a 12 week study period. Real-time air quality information and guidance provided by the online platform. |
|
有源比较器:Air Quality Information Not Provided
Participants receive the same 12-week progressive walking programme through the P-STEP platform, with the same exercise guidance and tracking functions, but without air-quality information or pollution-related guidance. |
Participants will receive a progressive, personalised walking exercise programme aimed to increase their weekly levels of physical activity over a 12 week study period. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Weekly time-weighted mean modelled ambient PM2.5 concentration during moderate-to-vigorous physical activity
大体时间:1-week baseline and weekly throughout the 12 week intervention
|
Time-stamped GPS/GNSS locations recorded by the P-STEP platform during Fitbit-derived moderate-to-vigorous physical activity (MVPA) will be linked to contemporaneous modelled ambient PM2.5 concentration estimates. Concentrations will be time-weighted across eligible MVPA periods to derive a weekly mean ambient PM2.5 concentration for each participant. |
1-week baseline and weekly throughout the 12 week intervention
|
|
Weekly time-weighted mean modelled ambient PM10 concentration during moderate-to-vigorous physical activity
大体时间:1-week baseline and weekly throughout the 12 week intervention
|
Time-stamped GPS/GNSS locations recorded by the P-STEP platform during Fitbit-derived moderate-to-vigorous physical activity (MVPA) will be linked to contemporaneous modelled ambient PM10 concentration estimates. Concentrations will be time-weighted across eligible MVPA periods to derive a weekly mean ambient PM10 concentration for each participant. |
1-week baseline and weekly throughout the 12 week intervention
|
|
Weekly time-weighted mean modelled ambient NO2 concentration during moderate-to-vigorous physical activity
大体时间:1-week baseline and weekly throughout the 12 week intervention
|
Time-stamped GPS/GNSS locations recorded by the P-STEP platform during Fitbit-derived moderate-to-vigorous physical activity (MVPA) will be linked to contemporaneous modelled ambient NO2 concentration estimates. Concentrations will be time-weighted across eligible MVPA periods to derive a weekly mean ambient NO2 concentration for each participant. |
1-week baseline and weekly throughout the 12 week intervention
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Weekly physical activity (weekly minutes, measured by wrist-worn accelerometry)
大体时间:1-week baseline and weekly throughout the 12-week intervention
|
Mean minutes of moderate to vigorous physical activity measured continuously over the 12-week intervention period using a wrist-worn accelerometer. The comparison will be change from baseline in mean weekly minutes between the air quality information and control arms at 12 weeks. |
1-week baseline and weekly throughout the 12-week intervention
|
合作者和调查者
调查人员
- 首席研究员:Andre Ng, Ph.D, MD、University of Leicester
出版物和有用的链接
一般刊物
- McCreanor J, Cullinan P, Nieuwenhuijsen MJ, Stewart-Evans J, Malliarou E, Jarup L, Harrington R, Svartengren M, Han IK, Ohman-Strickland P, Chung KF, Zhang J. Respiratory effects of exposure to diesel traffic in persons with asthma. N Engl J Med. 2007 Dec 6;357(23):2348-58. doi: 10.1056/NEJMoa071535.
- Sinharay R, Gong J, Barratt B, Ohman-Strickland P, Ernst S, Kelly FJ, Zhang JJ, Collins P, Cullinan P, Chung KF. Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, crossover study. Lancet. 2018 Jan 27;391(10118):339-349. doi: 10.1016/S0140-6736(17)32643-0. Epub 2017 Dec 5.
- Holgate ST. 'Every breath we take: the lifelong impact of air pollution' - a call for action. Clin Med (Lond). 2017 Feb;17(1):8-12. doi: 10.7861/clinmedicine.17-1-8.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 1058
- 348160 (注册表标识符:IRAS)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data will not be shared owing to the sensitive nature of the data collected, which includes continuous GPS-linked location tracking and personal physical activity monitoring. Sharing of granular location data at the individual level would risk re-identification of participants despite anonymisation. Aggregate summary data and analysis code will be made available upon reasonable request to the corresponding author following publication.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.